# Rani Therapeutics Posts $1.7 Million in Q3 Revenue, $0.04 GAAP Loss Per Share

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/53428
Published: 2026-11-11T00:19:25.000Z
Updated: 2026-11-11T00:19:25.000Z
Section: Business

> Cash, cash equivalents and marketable securities totaled $45.3 million on Sept. 30, 2026, down from $53.4 million on June 30. Rani expects those funds to cover operations through at least the end of 2027.

Rani Therapeutics Holdings, Inc. posted $1.7 million in third-quarter revenue and a GAAP loss of $0.04 per share, while its cash, cash equivalents and marketable securities declined between June and September.

The combined balance was $45.3 million on Sept. 30, 2026, compared with $53.4 million on June 30.

Rani expects those funds to cover operations through at least the end of 2027 under its current operating plan.